MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 897 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
KRAS G12D inhibitor 11
CAS:KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).Formula:C29H38BN5O3Color and Shape:SolidMolecular weight:515.45Refametinib R enantiomer
CAS:Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used
Formula:C19H20F3IN2O5SPurity:99.86%Color and Shape:SolidMolecular weight:572.34KRAS G12D inhibitor 9
CAS:KRAS G12D inhibitor 9 targets RAS protein, key in growth, showing promise against KRAS G12D cancer.Formula:C33H43N7O2Color and Shape:SolidMolecular weight:569.74G-479
CAS:G-479, a potent MEK inhibitor and improved analogue of GDC-0623, has distributed polarity enhancing bioactivity.Formula:C16H15FIN5O4Color and Shape:SolidMolecular weight:487.22LZTR1-KRAS modulator 1
CAS:LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.Formula:C11H11Cl2NOColor and Shape:SolidMolecular weight:244.12KRAS inhibitor-32
CAS:KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.Formula:C29H35FN10OS2Color and Shape:SolidMolecular weight:622.78KRAS G12D inhibitor 16
CAS:KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.Formula:C32H39IN6O3Color and Shape:SolidMolecular weight:682.59Calderasib
CAS:Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitorsFormula:C32H31ClF2N6O4Purity:98.69%Color and Shape:SolidMolecular weight:637.08BBO-8520
CAS:BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.Formula:C35H33F6N7O2SPurity:97.879%Color and Shape:SolidMolecular weight:729.74COTI-219
CAS:COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].Formula:C17H18N6SColor and Shape:SolidMolecular weight:338.43pan-KRAS-IN-6
CAS:Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.Formula:C29H30ClF3N6O3SColor and Shape:SolidMolecular weight:635.10KRASG12D-IN-3-d3
CAS:KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Formula:C31H27D3ClF6N7O2Color and Shape:SoildMolecular weight:685.08MRTX849 acid
CAS:MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.Formula:C34H37ClFN7O4Color and Shape:SolidMolecular weight:662.16KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Formula:C22H17ClF2N6OSColor and Shape:SolidMolecular weight:486.93Famlasertib
CAS:Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.Formula:C26H27ClN4OColor and Shape:SolidMolecular weight:446.972KRAS G12C inhibitor 33
CAS:KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63TH-Z816
CAS:TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].Formula:C29H38N6OColor and Shape:SolidMolecular weight:486.65HPK1-IN-41
CAS:HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].Formula:C28H33N5O2Color and Shape:SolidMolecular weight:471.59NHTD
CAS:NHTD, a KRAS-PDEδ inhibitor, exerts its function by targeting the isoprenyl binding pocket of PDEδ, which alters the cellular localization of KRAS. This modification restricts the proliferation of cancer cells with KRAS mutations and induces cell apoptosis (Apoptosis). NHTD is utilized in the study of KRAS-driven non-small cell lung cancer (NSCLC).Formula:C24H26N2O5Color and Shape:SolidMolecular weight:422.47KRAS inhibitor-34
CAS:KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.Formula:C43H41F3N6O3Color and Shape:SolidMolecular weight:746.82
